Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems

Inactive Publication Date: 2005-09-15
RGT UNIV OF CALIFORNIA
View PDF97 Cites 44 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016] Stable isotope-labeled substrates are incorporated into one or more molecules of one or more metabolic pathways of interest. In this manner, the molecular flux rates can be determined by measuring, over specific time intervals, isotopic content and / or pattern or rate of change of isotopic content and / or pattern in the targeted molecules, for example by using mass spectrometry, allowing for the determination of the molecular flux rates within the one or more metabolic pathways of interest, by use of analytic and calculation methods known in the art.
[0017] Alternatively, the use of radiolabeled substrates is contemplated for use in the present invention wherein the radiolabeled substrates are incorporated into one or more molecules of one or more metabolic pathways of interest. In this manner, the molecular flux rates can be determined by measuring radiation and / or radioactivity of the targeted molecules of interest within the one or more metabolic pathways of interest by using techniques well known in the art such as scintillation counting. The molecular flux rates within the one or more metabolic pathways of interest are then calculated, using methods known in the art.
[0018] In another embodiment of the invention, isolated isotopically perturbed molecules are provided, the isotopically perturbed molecules including one or more isotopes. The isolated isotopically perturbed molecules are products of the labeling methods described herein. The isolated isotopically perturbed molecules are collected by sampling techniques known in the art and are analyzed using appropriate analytical tools. In one embodiment of the invention, the isolated isotopically perturbed molecules are comprised of one or more stable isotopes. In another embodiment, the isolated isotopically perturbed molecules are comprised of one or more radioactive isotopes.
[0019] In yet another embodiment of the invention, one or more kits are provided that comprise isotope-labeled precursors and instructions for using them. The kits may contain stable-isotope labeled precursors or radioactive-labeled isotope precursors or both. Stable-isotope labeled precursors and radioactive-labeled isotope precursors may be provided in one kit or they may be separated and provided in two or more kits. The kits may further comprise one or more tools for administering the isotope-labeled precursors. The kits also may comprise one or more tools for collecting samples from a subject.
[0020] In yet another embodiment of the invention, one or more information storage devices are provided that comprise data generated from the methods of the present invention. The data may be analyzed, partially analyzed, or unanalyzed. The data may be imprinted onto paper, plastic, magnetic, optical, or other medium for storage and display.
[0021] In yet another embodiment of the invention, one or more compounds, combinations of compounds, or mixtures of compounds identified and at least partially characterized by the methods of the present invention are contemplated.

Problems solved by technology

The metabolic action of the compound (or combination of compounds or mixture of compounds) on the exposed cell, tissue or organism may be unexpected or unanticipated (based on prevailing biochemical knowledge and concepts about the compound and molecular flux within the pathway) or may be anticipated or expected.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
  • Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
  • Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems

Examples

Experimental program
Comparison scheme
Effect test

example 1

Measurement of Triglyceride (TG) Synthesis (Lipogenesis) and Breakdown (Lipolysis) in Rats after Exposure to Compounds

[0239] To assess whether a compound inhibits lipogenesis (and therefore, a candidate drug for treating obesity or other metabolic disorders) Sprague-Dawley rats (200-300 g Simonsen Labs, Gilroy, Calif.) are either exposed to a compound or left unexposed (i.e., controls). Rats are administered compound or vehicle via gavage. One or several compounds may be administered. For example, thousands of compounds may be initially screened, pooled, rescreened, subpooled, etc., to screen for one or more active compounds. An initial priming dose of 99.8% 2H2O is given via intraperitoneal injection to achieve ca. 2.5% body water enrichment (assuming 60% body weight as water) followed by administration of 4% 2H2O in drinking water for up to 12 weeks.

[0240] Adipose tissue samples are placed in dual glass tissue grinders (e.g., Kontes tissue grinders, Kimble Kontes, Vineland, N.J....

example 2

Measurement of DNA Synthesis and Breakdown in Rats after Exposure to Compounds

[0250] DNA synthesis is a biomarker for cell proliferation. In some settings it may be desirable to stimulate cell proliferation (e.g., to stimulate wound healing) while in other settings it may be desirable to inhibit cell proliferation (e.g., cancer).

[0251] Rats are administered 2H2O as discussed in Example 1, supra.

[0252] Rats are either administered compounds (or combinations of compounds or mixtures of compounds) or vehicle (controls) as discussed in Example 1, supra.

[0253] DNA is then isolated from the tissue or cell of interest using a Qiagen kit (Qiagen, Valencia, Calif.), following the manufacturer's protocol.

[0254] Isotope enrichment is then analyzed and flux rates calculated as described, supra. DNA synthesis is then determined as described, supra, (and in U.S. Pat. No. 5,910,403, incorporated by reference). Compound-exposed animals are then compared to unexposed animals to determine if the...

example 3

Measurement of Neurogenesis in Rat Hippocampal Neuroprogenitor Cells after Exposure to Compounds

[0255] Compounds (or combinations of compounds or mixtures of compounds) are tested on rats to determine whether one or more may have effects on neurogenesis. Compounds with neurogenic potential may find use in treating spinal cord injury, Parkinson's disease, Huntington's disease and other neurodegenerative disorders. Rats are divided into exposed and control groups and administered labeled water as in Example 1, supra. After exposure to compound or combinations of compounds or mixtures of compounds (or vehicle if control rat), by gavage, intrathecal, or intracranial administration (route of administration is dependent on the chemistry of the compound or combination of compounds or mixture of compounds, as is well known in the art) rats are deeply anesthetized with a mixture of ketamine, xylazine, and acepromazine. Rats are then decapitated and whole brains are removed.

[0256] For isola...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar concentrationaaaaaaaaaa
natural abundanceaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

The invention enables high-throughput screening of compounds in living systems to detect unanticipated or unintended biological actions. The invention also allows for screening, detection, and confirmation of new indications for approved drugs. Screening and detection of toxic effects of compounds also can be achieved by using the methods of the invention. The methods comprise administering isotope-labeled substrates to a living system so that the label is incorporated into molecules in a manner that reveals flux rates through metabolic pathways thought to be involved in a disease. Comparisons between living systems exposed to compounds and living systems not so exposed reveals the effects of the compounds on the flux rates through the metabolic pathways. Combinations or mixtures of compounds can be systematically screened to detect unanticipated or unintended biological actions, including synergistic actions, in the same manner.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 525,261 filed Nov. 25, 2003, the disclosure of which is incorporated herein by referenced in its entirety.FIELD OF THE INVENTION [0002] The invention relates to methods for screening compounds, combinations of compounds, or mixtures of compounds (i.e., drugs and drug candidates, including chemical entities, whether new or known, and biological factors, whether new or known) for actions in biological systems. The disclosed methods measure and quantify molecular flux rates through metabolic pathways (synthesis and breakdown or input and removal rates from pools of molecules) in vivo as targets of drug action. The disclosed methods are capable of high-throughput, large-scale, automated applications. The methods are particularly applicable to detecting and establishing unanticipated or unintended actions of drugs or drug candidates during drug discovery, d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K49/00C12Q1/00C12Q1/68G01N33/48G01N33/50G06F19/00
CPCA61K49/0008G01N33/5088G01N33/5067G01N33/6848G01N33/60Y02A90/10
Inventor HELLERSTEIN, MARC K.
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products